Physician profile

Lydia Pecker

Pediatric Hematology-Oncology · Baltimore, MD

NPI 1891074233

$40,579.99

in general payments reported to CMS, 2019-2025

6 companies · $22K in 2025

The $22K reported for 2025 was more than what 92% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$15,700.00
Travel and Lodging$12,722.61
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$723.94
Food and Beverage$534.52

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pfizer INC. $21,082.23 2025
Novo Nordisk INC $12,134.95 2022-2023
Global Blood Therapeutics, INC. $5,401.45 2022
Alexion Pharmaceuticals, INC. $1,409.87 2023
E.R. Squibb & Sons, L.L.C. $551.49 2025

1 company reported research payments only; those appear in the research section below.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lydia Pecker

$40,579.99

in general payments reported 2019-2025

Years
2022-2025
Top company
Pfizer INC.
Context
The $22K reported for 2025 was more than what 92% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).

https://glasscript.com/doctor/5550249/lydia-pecker

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.